109. Atypical hemolytic uremic syndrome Clinical trials / Disease details
Clinical trials : 115 / Drugs : 37 - (DrugBank : 7) / Drug target genes : 3 - Drug target pathways : 10
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04749810 (ClinicalTrials.gov) | December 19, 2019 | 8/2/2021 | Observational Study of Elizaria® in aHUS Patients | Prospective Observational Study of Long-term Pathogenic Treatment of Elizaria® in Patients With Atypical Hemolytic Uremic Syndrome | Atypical Hemolytic Uremic Syndrome;aHUS | Drug: Elizaria® | AO GENERIUM | NULL | Recruiting | 2 Months | N/A | All | 50 | Russian Federation |